Please login to the form below
Alexion Pharmaceuticals
This page shows the latest Alexion Pharmaceuticals news and features for those working in and with pharma, biotech and healthcare.
BMS pledges $300m to tackle health inequity and improve diversity
Earlier this month, Alexion Pharmaceuticals appointed its first chief diversity officer, with Uzair Qadeer taking on the role after serving as head of enterprise partnerships at the company.
Latest news
-
Shire links with US hospital for rare disease research
It already has a rare and complex disease collaboration with Alexion Pharmaceuticals - which it describes as a "model for how industry and academia can better work together to bring health innovations
-
Assessing drugs for ultra-rare conditions in the UK
Alexion’s Soliris has become the first drug to pass through NICE’s new highly specialised technology process. ... No quick solution. Jon Beauchamp, business unit leader PNH/aHUS at Alexion Pharmaceuticals, told PME: “It's certainly been a very
-
Alexion begins work on new global headquarters
From left: New Haven Mayor John DeStefano, Sen. Richard Blumenthal, Governor Dan Malloy, Alexion CEO Leonard Bell, Rep. ... Alexion Pharmaceuticals has broken ground on the site for its new global headquarters in New Haven, Connecticut.
-
PDL BioPharma CEO will quit despite being cleared of misconduct
PDLs litigation with Alexion Pharmaceuticals. ... Link is chairman of Alexion, while PDL has filed a patent infringement lawsuit against the company.
More from news
Approximately 0 fully matching, plus 5 partially matching documents found.
Latest Intelligence
-
Deal Watch table for January 2014
144. Moderna Therapeutics/ Alexion Pharmaceuticals. Exclusive discovery and development. Messenger RNA (mRNA) therapeutics in rare diseases for 10 product options. ... 100. Cancer Prevention Pharmaceuticals/ Zeria Tillotts Pharma. Exclusive licensing
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest appointments
-
New faces at Merus, Rubius Therapeutics and Titan Pharmaceuticals
Prior to CRISPR, he worked as head of translational medicine at Alexion Pharmaceuticals, and also served as chief medical officer of Taligen Therapeutics. ... Cagnoni, chief executive officer of Rubius. Titan Pharmaceuticals. Kate DeVarney has joined
-
Amryt Pharma appoints Jordi Casals as head of Europe
He joins the company from Aegerion Pharmaceuticals. Amryt Pharma, a company focused on treatments for rare and orphan diseases, has appointed Jordi Casals as the biopharma’s head of Europe. ... Prior to this, he worked for eight years at Alexion
-
Alexion Pharmaceuticals adds to its board
Judith Reinsdorf recently worked at Johnson Controls. Alexion Pharmaceuticals has appointed Judith Reinsdorf to its board of directors following her role as executive vice president and general counsel of Johnson Controls. ... David Brennan, chairman of
-
Belgium's TiGenix appoints Dr Gregory Gordon
Dr Gordon joins TiGenix from Nestlé Health Science, where he was global clinical affairs lead, gastrointestinal health and prior to that he has worked at Stealth BioTherapeutics, Ironwood Pharmaceuticals and Parexel. ... Meanwhile, Valles-Sukkar arrives
-
Minoryx Therapeutics adds to board of directors
Dr Nicaise founded Clinical Regulatory Services, a biotech-focused advisory service, in 2014, having previously served as senior vice president of strategic development and global regulatory affairs at Alexion Pharmaceuticals from
More from appointments
Approximately 1 fully matching, plus 8 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
-
Healthcare Lead Copywriter
-
Competitive
-
Healthcare Senior Account Manager
-
Competitive
-
Medical Editor
-
Competitive
- Sales Director, Healthcare communications agency, London/ SE UK
-
Six figure salary
- Account Manager Healthcare / Pharmaceutical Sector
-
Negotiable Salary
-
Healthcare Account Director
-
Competitive
- Nucleus Global announces a trio of promotions
- Sanofi, GSK delay COVID-19 vaccine trial after underwhelming results in elderly participants
- Pfizer introduces new logo in a ‘shift from commerce to science’
- New study identifies drugs that are safe to use in COVID-19 treatment
- PHE study finds people who have had COVID-19 can still transmit the virus
- Bayer’s finerenone scores FDA priority review for chronic kidney disease
- Mistrust in medical research: a patient perspective
- Real-world evidence: breaking boundaries in rare disease
- Live Webinar: Importance of Highlighting Patient Voices, Workforce Well-Being, and Health Literacy During and After the Pandemic
- The heavy toll of COVID-19 on cancer patients
- Unpacking rare diseases in the first edition of Delta magazine
- Virtual HealthTech conference powered by Impetus Digital: A Customer Story
PMHub
90TEN
90TEN is a global healthcare communications consultancy with a mission to make people healthier and happier through life-changing education and...
Latest intelligence
- Mistrust in medical research: a patient perspective
- The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
- Real-world evidence: breaking boundaries in rare disease
- Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...
- The heavy toll of COVID-19 on cancer patients
- We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of...
Quick links
Infographics
